Series A11 January 2023

Inflow secures £9m in Series A funding led by Octopus Ventures to support product development.

Octopus Ventures led the Series A round with participation from Hoxton Ventures and Route66 Ventures.

£9.0MSeries A

Inflow operates a science-based digital platform that provides cognitive behavioural therapy support for individuals managing ADHD. The company aims to make care more accessible by offering practical tools and community events.

Digital support platform Inflow has secured £9m in a Series A funding round led by Octopus Ventures. The financing also saw participation from returning backers Hoxton Ventures and Route66 Ventures, alongside several angel investors. The capital will be deployed to support ongoing product development and expand the company team.

Established in 2020, Inflow delivers cognitive behavioural therapy techniques via an application designed to help users navigate daily routines and build self-regulation habits. The latest investment follows preliminary testing showing reductions in reported symptoms among platform members. Will Gibbs of Octopus Ventures will join the company board as part of the transaction.

From the founder

"Diagnosing and treating ADHD can be a long and costly process, and living with the symptoms can be extremely challenging. We want to help our members make significant improvements to their quality of life by giving them the tools to better understand themselves, and implement coping strategies that actually work."

Seb Isaacs

Co-founder at Inflow

Investor perspective

"People with ADHD represent around 10% of the global population and Inflow is offering a new way to help them access the most effective support. The team has built a community of users who are already seeing a real impact on their lives and Inflow’s B2C “global from day 1” approach means there is an opportunity to quickly reach meaningful scale. We believe Inflow can become a world-changing business making a huge impact on people’s lives, and not just those with ADHD but in a range of neurological areas in the future."

Will Gibbs

Healthtech Partner, Octopus Ventures